Appeal No. 1999-0031
Application No. 08/168,438
31. A method for treating a body fluid to at least substantially inactivate
viral contaminants that may be present therein comprising the steps of:
providing a therapeutically useful body fluid;
adding to the body fluid a viral inactiavating agent in an amount and under
conditions effective to at least substantially inactivate any viral contaminants
present in the body fluid without destroying therapeutic benefits of the body fluid
to form a resultant product;
passing the resultant product through a column including macroporous
polymeric beads having an affinity for the viral inactivating agent phtoproducts
generated by irradiating the viral inactivating agent with light; and
selectively removing all measurable viral inactivating agent and
photoproducts, as determined by high pressure liquid chromatography, from the
resultant product by allowing the viral inactivating agent and the photoproducts to
bind to the macroporous polymeric beads, without destroy9ng the therapeutic
benefits of the body fluid to provide a treated body fluid suitable for administration
to a patient.
6. The method of Claim 31 wherein the viral inactivating agent is a
light activated viral inactivating agent selected from the group consisting of:
porphyrin; psoralen; phthalocyanine; and hypericin; and dye.
9. The method of Claim 31 wherein the macroporous polymeric beads
have the following characteristics:
polarity – non-polar to intermediate polarity;
dipomoment - 0.1 to 3.0;
bead size – 30 to 2,000;
average pore diameter – 45 to 300 angstroms; and
bead surface area – 15 to 1,600 square meters per gram dry bead.
The examiner relies on the following references:
Hodgson et al. (Hodgson) 4,190,542 Feb. 26, 1980
Sugiyama et al. (Sugiyama) 4,728,432 Mar. 1, 1988
Australian Patent Application
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007